AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 May 2020 07:00 AM
RNS
Bevespi Aerosphere approved in China for COPD
18 May 2020 07:00 AM
RNS
Enhertu US Breakthrough status for lung cancer
11 May 2020 07:00 AM
RNS
Lynparza gets broader US ovarian cancer approval
11 May 2020 07:00 AM
RNS
Brazikumab rights recovered by AstraZeneca
11 May 2020 07:00 AM
RNS
Enhertu designated gastric cancer BTD
06 May 2020 07:00 AM
RNS
Farxiga approved by FDA for heart failure (HFrEF)
01 May 2020 03:00 PM
RNS
Total Voting Rights
29 Apr 2020 04:00 PM
RNS
Result of AGM
29 Apr 2020 07:00 AM
RNS
AZN: first-quarter 2020 results
24 Apr 2020 07:00 AM
RNS
Lynparza shows overall survival in prostate cancer
17 Apr 2020 11:00 AM
RNS
Changes to arrangements for AGM
14 Apr 2020 07:00 AM
RNS
Tagrisso adjuvant trial overwhelmingly positive
14 Apr 2020 07:00 AM
RNS
Koselugo (selumetinib) approved in the US for NF1
02 Apr 2020 07:00 AM
RNS
AstraZeneca divestment of Movantik completed
01 Apr 2020 03:00 PM
RNS
Total Voting Rights
31 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
30 Mar 2020 07:01 AM
RNS
Imfinzi approved in US for small cell lung cancer
30 Mar 2020 07:00 AM
RNS
Farxiga CKD trial early stop for positive efficacy
26 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
26 Mar 2020 07:00 AM
RNS
Lokelma approved in Japan for hyperkalaemia
24 Mar 2020 04:41 PM
RNS
Second Price Monitoring Extn
24 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
24 Mar 2020 12:02 PM
RNS
Price Monitoring Extension
23 Mar 2020 04:40 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 04:36 PM
RNS
Price Monitoring Extension
23 Mar 2020 12:08 PM
RNS
Second Price Monitoring Extn
23 Mar 2020 12:03 PM
RNS
Price Monitoring Extension
20 Mar 2020 10:20 AM
RNS
Second Price Monitoring Extn
20 Mar 2020 10:15 AM
RNS
Price Monitoring Extension
20 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Mar 2020 07:00 AM
RNS
Lynparza granted orphan drug designation in Japan
17 Mar 2020 07:00 AM
RNS
Imfinzi confirmed overall survival in CASPIAN
13 Mar 2020 04:35 PM
RNS
Price Monitoring Extension
12 Mar 2020 11:00 AM
RNS
Notice of AGM
12 Mar 2020 07:00 AM
RNS
Update on Phase III GY004 trial for cediranib
10 Mar 2020 07:00 AM
RNS
Director/PDMR Shareholding
06 Mar 2020 07:00 AM
RNS
Update on Phase III DANUBE trial in bladder cancer
04 Mar 2020 07:00 AM
RNS
Filing of Form 20-F with SEC
03 Mar 2020 11:00 AM
RNS
Annual Financial Report
02 Mar 2020 03:00 PM
RNS
Total Voting Rights
02 Mar 2020 07:00 AM
RNS
Divestment of hypertension medicines completed
27 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
25 Feb 2020 07:00 AM
RNS
AstraZeneca divests global rights to Movantik
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
19 Feb 2020 07:00 AM
RNS
Director/PDMR Shareholding
14 Feb 2020 07:00 AM
RNS
AZN: Full-year and Q4 2019 results
03 Feb 2020 03:00 PM
RNS
Total Voting Rights
27 Jan 2020 07:00 AM
RNS
Enhertu Phase II trial met primary endpoint
27 Jan 2020 07:00 AM
RNS
Brilinta met primary endpoint in stroke trial
27 Jan 2020 07:00 AM
RNS
AstraZeneca divests hypertension medicines

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings